查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1990330

固态器官移植排斥反应市场：依排斥反应类型、移植方式、器官类型及最终用户划分－2026-2032年全球市场预测

Solid Organ Transplantation Rejection Market by Rejection Type, Offering, Organ Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，固态器官移植排斥反应市场价值将达到 91.9 亿美元，到 2026 年将成长至 96.7 亿美元，到 2032 年将达到 134.1 亿美元，复合年增长率为 5.54%。

主要市场统计数据
基准年 2025 91.9亿美元
预计年份：2026年 96.7亿美元
预测年份 2032 134.1亿美元
复合年增长率 (%) 5.54%

固态器官移植排斥反应的临床、诊断和治疗环境不断变化，以及综合护理路径和创新面临的策略挑战。

固态器官移植仍然是现代医学中最具突破性的治疗方法之一，但排斥反应仍然是临床和运作中面临的核心挑战。随着手术效果的改善，人们的关注点正转向导致急性、慢性及超急性排斥反应的各种免疫反应，每种反应都需要独特的诊断、监测和治疗方法。随着免疫学、诊断学和治疗学之间相互作用的不断发展，临床医生、医院系统、製造商和保险公司需要重新评估治疗路径及其相关基础设施。

诊断、治疗、数位整合、监管重点和跨部门合作方面的变革性转变正在重塑移植排斥反应的检测和管理方式。

目前，移植排斥反应的管理正经历多项平行变革，这些变革共同重塑治疗标准。其中一项关键变革是精准诊断技术的成熟。血液检测、先进影像技术和精密组织切片检查技术的融合，使得免疫介导性疾病的早期和特异性检测成为可能。诊断技术的进步与免疫调节药物的改进相辅相成，包括先进的抗体疗法、标靶抗代谢药物、优化的Calcineurin酶抑制剂方案以及类固醇减量策略，这些都为更个人化的免疫抑制疗法创造了可能，从而降低排斥反应和长期毒性。

本研究评估了 2025 年起生效的美国关税变化将如何影响移植医学的器官来源、製造地、国际合作和供应链韧性。

自2025年起，美国将实施关税，这将进一步加剧现有供应链的压力，促使移植医学领域的众多相关人员重新评估筹资策略。血液检测、影像平台和组织切片检查处理中使用的设备和试剂通常依赖跨国供应链。因此，不断上涨的进口成本和日益复杂的海关程序正在影响采购决策、库存管理和供应商多元化。为此，一些移植中心和专科诊所正在加快关键库存在地采购的步伐，协商签订多年期供应商合同，或采用使用更多国内可得组件的替代技术。

针对特定细分市场的洞察，整合了排斥表型、诊断方法、治疗药物分类、器官特异性考虑因素以及医疗保健环境的影响，从而指导策略优先排序。

透过检验构成移植排斥反应管理的关键环节，可以更深入了解市场动态。从排斥反应类型来看，急性排斥反应需要快速诊断和立即进行免疫抑制；慢性排斥反应需要长期监测和采取措施来减轻移植器官的进行性劣化；而超急性排斥反应则需要在术前和术后即时进行识别和干预。因此，每种排斥反应表型都有其独特的临床重点和技术要求。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和采用模式决定了研究重点、临床整合以及移植创新成果的取得途径。

区域差异显着影响着预防和管理移植排斥反应的创新技术如何引入并融入医疗保健系统。在美洲，高移植中心和完善的报销机制通常有利于先进诊断技术和新型治疗方法的快速应用，而区域间医疗资源取得的差异则需要采取针对性措施来扩大医疗能力并确保医疗服务的公平性。在欧洲、中东和非洲，法律规范和医疗体系模式各不相同。因此，技术的实施往往不均衡，学术机构和国家级医院主导临床研究和最佳实践的推广，而其他地区则专注于实用且资源高效的方案。

这种竞争与合作的企业洞察揭示了诊断技术创新者、治疗方法开发商和供应链策略家为获得临床和营运领导地位而采取的策略。

移植排斥反应管理领域的竞争格局呈现出成熟医疗公司与专业创新企业并存的局面，双方携手合作，共同推动技术进步与临床应用。诊断公司正投资开发可扩展的高灵敏度血液检测和组织分析平台，而影像供应商则专注于增强移植监测和功能评估的影像方式。製药和生物技术公司持续优化免疫抑制疗法，并推进针对特定免疫路径的抗体和小分子药物的研发，他们通常与学术机构合作，以检验临床终点和安全性。

为高阶主管和临床领导者提供实用建议，以加快诊断技术的采用，加强供应链，协调伙伴关係关係，并在所有医疗保健机构中扩大公平获取途径。

产业领导者应推动一系列合作倡议，将科学进步转化为移植存活率和患者预后的可衡量改善。首先，优先投资于能够实现早期、非侵入性检测的诊断技术，将提高临床应对力，并减少对侵入性手术的依赖。其次，将由可互通的医疗资讯科技、决策支援和临床医生培训支援的「诊断到治疗演算法」整合到临床工作流程中，将加速其应用，并提高各医院、移植中心和专科诊所之间护理的一致性。此外，各机构应建立策略伙伴关係，将诊断设备製造商、药物开发商和研究机构联合起来，共同设计检验研究和真实世界数据（REW）项目，以证明其在心臟、肾臟、肝臟、肺臟和胰臟移植领域的临床效用。

我们研究途径透明的混合方法，结合同侪审查的证据、主要专家访谈和操作检验，得出可靠且可操作的结论。

本报告的分析采用了一种严谨的混合方法研究途径，旨在确保其可靠性、相关性和实用性。二级研究包括对同行评审的临床文献、监管申报文件和公开技术文件进行系统性回顾，以描述各种排斥表型的诊断技术、治疗机制和临床管理策略。此外，还开展了一级研究，包括对移植临床医生、实验室管理人员、器官捐赠者和行业高管进行结构化访谈，以了解他们对未满足需求、推广障碍和实际应用驱动因素的观点。

结论整合了临床和策略需求，透过诊断、治疗、协调和稳健的安置策略来提高移植存活率。

固态器官移植正处于科学创新、临床实务和系统性考量交会的十字路口，这些因素共同影响着病患的预后。诊断和治疗方法的进步具有降低急性、慢性及超急性排斥反应发生率和影响的真正潜力，但要实现这一潜力，需要製造商、临床医生、医疗系统和政策制定者之间的通力合作。对非侵入性监测、实证医学、可互通的工作流程和稳健的供应链进行策略性投资，对于将科学进步转化为日常临床效益至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：固态器官移植的市场排斥－排斥的类型

  • 急性排斥反应
  • 慢性排斥
  • 超急性排斥

第九章：固态器官移植排斥反应市场：依产品供应情况划分

  • 诊断和测试解决方案
    • 验血
    • 影像检查
    • 组织切片检查
  • 製药
    • 抗体
    • 抗代谢物
    • Calcineurin抑制剂
    • 类固醇

第十章：固态器官移植排斥反应－按器官类型分類的市场

  • 心
  • 肾
  • 肝
  • 肺
  • 胰臟

第十一章：固态器官移植排斥市场：依最终使用者划分

  • 医院及移植中心
  • 研究机构
  • 专科诊所

第十二章：固态器官移植排斥反应市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：固态器官移植排斥反应市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：固态器官移植排斥反应市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国固态器官移植排斥市场

第十六章：中国固态器官移植排斥反应市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Accord Healthcare Limited
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Biocon
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eurofins Transplant Diagnostics
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Globela Pharma
  • Lupin Limited
  • Manus Aktteva Biopharma LLP
  • Natco Pharma Ltd.
  • Novartis AG
  • Panacea Biotec Pharma Ltd.
  • Pfizer Inc.
  • Plexision
  • Sanofi SA
  • Strides Pharma Global Pte Ltd.
  • Thermo Fisher Scientific Inc.
  • Veloxis Pharmaceuticals A/S
  • Zydus Lifesciences Limited
Product Code: MRR-CB04E05661AD

The Solid Organ Transplantation Rejection Market was valued at USD 9.19 billion in 2025 and is projected to grow to USD 9.67 billion in 2026, with a CAGR of 5.54%, reaching USD 13.41 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.19 billion
Estimated Year [2026] USD 9.67 billion
Forecast Year [2032] USD 13.41 billion
CAGR (%) 5.54%

Introducing the evolving clinical, diagnostic, and therapeutic environment of solid organ transplant rejection and the strategic imperatives for integrated care pathways and innovation

Solid organ transplantation remains one of the most transformative interventions in modern medicine, yet rejection continues to be a central clinical and operational challenge. As surgical outcomes have improved, attention has shifted to the heterogenous immune responses that lead to acute, chronic, and hyperacute rejection, each of which demands distinct diagnostic, monitoring, and therapeutic approaches. The evolving interplay between immunology, diagnostics, and therapeutics requires clinicians, hospital systems, manufacturers, and payers to re-evaluate care pathways and the supporting infrastructure.

In recent years, advances in molecular diagnostics and noninvasive monitoring have opened new possibilities for earlier detection and individualized immunosuppression, while therapeutic innovations seek to balance efficacy with long-term safety. At the same time, differences in transplanted organs-such as the physiologic and immunologic nuances of heart, kidney, liver, lung, and pancreas transplantation-shape both clinical practice and product development. Consequently, stakeholders must synthesize evidence across rejection type, diagnostic and medication offerings, organ-specific considerations, and the diverse environments in which transplant care is delivered. This introduction sets the context for a focused examination of those elements and frames the priorities that will guide clinical effectiveness, patient outcomes, and system-level value creation.

Transformative shifts in diagnostics, therapeutics, digital integration, regulatory focus, and cross-sector collaboration that are reframing how transplant rejection is detected and managed

The landscape of transplant rejection management is undergoing several parallel transformations that together are redefining standards of care. One primary shift is the maturation of precision diagnostics: blood-based assays, advanced imaging modalities, and refined tissue biopsy techniques are converging to enable earlier and more specific detection of immune-mediated injury. These diagnostic advances are complemented by improvements in immunomodulatory medications, including refined antibody therapies, targeted antimetabolites, optimized calcineurin inhibitor regimens, and steroid minimization strategies, creating opportunities for more individualized immunosuppression that reduces both rejection and long-term toxicity.

Alongside clinical innovations, digital health and data integration are changing how monitoring and decision-making occur. Remote patient monitoring, algorithmic risk stratification, and interoperable electronic health records are facilitating more proactive care and tighter coordination among transplant centers, specialty clinics, and research institutes. Regulatory and reimbursement environments are also shifting their focus toward evidence of clinical utility and cost-effectiveness, which incentivizes the development of diagnostics and therapeutics that demonstrate clear impact on outcomes. Finally, partnerships across industry, academic centers, and clinical networks are accelerating translational research and multicenter validation of novel tools. Taken together, these transformative shifts are producing a more responsive, evidence-driven approach to preventing and managing acute, chronic, and hyperacute rejection across organ types.

Assessing how United States tariff changes beginning in 2025 are reshaping procurement, manufacturing footprints, international collaborations, and supply chain resilience for transplant care

The introduction of tariffs in the United States beginning in 2025 has compounded preexisting supply chain pressures and prompted a reevaluation of procurement strategies for many stakeholders involved in transplantation care. Devices and reagents used in blood tests, imaging platforms, and tissue biopsy processing often rely on multinational supply chains; increased import costs and customs complexity have therefore influenced sourcing decisions, inventory practices, and supplier diversification. As a result, some transplant centers and specialty clinics have accelerated efforts to localize critical inventories, negotiate multi-year supplier agreements, or adopt alternative technologies with more domestically available components.

In addition to procurement adaptations, tariffs have affected collaborative dynamics with international research partners and manufacturers. Cross-border clinical trials and technology transfer arrangements have required greater attention to total landed cost, regulatory alignment, and contingency planning. Manufacturers and distributors have responded by reassessing manufacturing footprints, increasing redundancy in critical nodes of the supply chain, and prioritizing transparency in lead times and component provenance. While these adjustments have the potential to increase resilience, they also introduce transitional operational costs and require closer coordination between hospitals, transplant centers, and research institutes to maintain uninterrupted access to diagnostics and therapies. Ultimately, the cumulative impact of tariffs has underscored the need for strategic procurement, robust supplier relationships, and operational flexibility across the transplantation ecosystem.

Segment-driven insights synthesizing rejection phenotypes, diagnostic modalities, therapeutic classes, organ-specific considerations, and care setting influences to guide strategic prioritization

A nuanced understanding of market dynamics emerges by examining the key segments that define transplant rejection management. When viewing the field through the lens of rejection type, acute rejection demands rapid diagnostic clarity and responsive immunosuppression, chronic rejection requires long-term monitoring and strategies to mitigate progressive graft deterioration, and hyperacute rejection necessitates immediate perioperative recognition and intervention. Each rejection phenotype thus imposes distinct clinical priorities and technology requirements.

From the perspective of offerings, diagnostics and testing solutions encompass blood tests that permit noninvasive surveillance, imaging tests that characterize structural and perfusion changes, and tissue biopsy procedures that provide histopathologic confirmation; medications include antibody agents that modulate humoral responses, antimetabolites that interfere with lymphocyte proliferation, calcineurin inhibitors that suppress T-cell activity, and steroids used for both induction and rescue therapy. These categories interact differently across organ types: heart, kidney, liver, lung, and pancreas transplantation each present unique immunologic profiles and clinical surveillance needs that influence the choice and sequencing of diagnostics and therapeutics. Finally, end-user settings such as hospitals and transplant centers deliver comprehensive perioperative and long-term care, research institutes drive translational innovation and validation studies, and specialty clinics often support outpatient monitoring and medication optimization. An integrated view of these segmentations clarifies where clinical unmet needs intersect with technological capabilities and operational realities, enabling stakeholders to prioritize investment, development, and implementation strategies that align with organ-specific and care-setting requirements.

Regional patterns and adoption dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine research focus, clinical integration, and access to transplant innovations

Regional variation profoundly affects how innovations in transplant rejection prevention and management are adopted and integrated into care. In the Americas, high-volume transplant centers and established reimbursement pathways often support rapid uptake of advanced diagnostics and novel therapeutics, while regional disparities in access require targeted initiatives to expand capacity and equitable care. Europe, Middle East & Africa exhibit heterogeneous regulatory frameworks and health system models; as a result, adoption tends to be uneven, with academic centers and national reference hospitals leading in clinical research and the diffusion of best practices, while other areas focus on pragmatic, resource-efficient approaches.

Across Asia-Pacific, rising transplant volumes and substantial investments in biotechnology and diagnostics have spurred local innovation and manufacturing, contributing to an expanding pipeline of regionally developed tools. However, differences in population demographics, disease etiologies, and care infrastructure mean that clinical pathways and monitoring strategies are often adapted to local contexts. These geographic distinctions also influence collaborative research priorities, the design of multicenter studies, and the scalability of solutions, underscoring the importance of tailoring implementation plans and commercialization strategies to regional strengths, regulatory expectations, and health system realities.

Competitive and collaborative company insights revealing how diagnostics innovators, therapeutic developers, and supply chain strategists are positioning to capture clinical and operational leadership

The competitive landscape in transplant rejection management is characterized by a mix of established healthcare companies and specialized innovators that together drive technological progress and clinical adoption. Diagnostic firms are investing in high-sensitivity blood-based assays and scalable platforms for tissue analysis, while imaging vendors focus on modalities that enhance graft surveillance and functional assessment. Pharmaceutical and biotech companies continue to refine immunosuppressive regimens and advance antibody and small-molecule programs that target specific immune pathways, often collaborating with academic centers to validate clinical endpoints and safety profiles.

Strategic partnerships, co-development agreements, and licensing arrangements are common as organizations seek to combine diagnostic precision with therapeutic innovation. In addition, manufacturers are responding to supply chain pressures by diversifying supplier networks and exploring near-shore manufacturing to reduce vulnerability to international disruptions. Overall, the market exhibits a pragmatic balance between competition and collaboration: firms that demonstrate interoperability with clinical workflows, robust evidence of clinical utility, and reliable supply chains are best positioned to form durable relationships with hospitals, transplant centers, and research institutes.

Actionable recommendations for senior executives and clinical leaders to accelerate diagnostic adoption, strengthen supply chains, align partnerships, and expand equitable access across care settings

Industry leaders should pursue a set of coordinated actions to translate scientific advances into measurable improvements in graft longevity and patient outcomes. First, prioritizing investments in diagnostics that enable earlier, noninvasive detection will improve clinical responsiveness and reduce reliance on more invasive procedures. Secondly, embedding diagnostic-to-therapy algorithms into clinical workflows-supported by interoperable health IT, decision support, and clinician training-will accelerate adoption and improve consistency of care across hospitals, transplant centers, and specialty clinics. Moreover, organizations should pursue strategic partnerships that unite diagnostic makers, pharmaceutical developers, and research institutes to co-design validation studies and real-world evidence programs that demonstrate clinical utility across heart, kidney, liver, lung, and pancreas transplantation.

From an operational perspective, supply chain diversification and transparent supplier relationships are essential to mitigate the downstream effects of trade policies and component shortages. Leaders must also focus on equitable access strategies that address geographic disparities and support capacity building where adoption lags. Finally, corporate and clinical stakeholders should invest in post-market surveillance and longitudinal registries to better understand patterns of acute, chronic, and hyperacute rejection and to refine therapeutic strategies over time. Taken together, these actions will help organizations reduce clinical variability, optimize resource utilization, and expand patient access to state-of-the-art monitoring and treatment.

Transparent mixed-methods research approach integrating peer-reviewed evidence, primary expert interviews, and operational validation to ensure robust and actionable conclusions

The analysis underpinning this report combines a rigorous, mixed-methods research approach designed to ensure credibility, relevance, and practical utility. Secondary research included a systematic review of peer-reviewed clinical literature, regulatory filings, and publicly available technical documentation to characterize diagnostic technologies, therapeutic mechanisms, and clinical management strategies for different rejection phenotypes. This evidence base was supplemented by primary research consisting of structured interviews with transplant clinicians, laboratory directors, procurement officers, and industry executives to capture frontline perspectives on unmet needs, implementation barriers, and practical adoption drivers.

Qualitative findings were validated through expert workshops and cross-checked against operational indicators reported by transplant centers and specialty clinics. Where appropriate, sensitivity analyses and scenario planning were used to explore the effects of supply chain disruptions and policy changes on procurement and clinical continuity. Throughout, quality controls included source triangulation, transparency in assumptions, and iterative review by clinical subject-matter experts to ensure that conclusions reflect current practice and emerging trends in diagnostics, therapeutics, and care delivery.

Conclusion synthesizing clinical and strategic imperatives for improving graft longevity through diagnostics, therapeutics, collaboration, and resilient implementation strategies

Solid organ transplantation sits at a crossroads where scientific innovation, clinical practice, and system-level considerations converge to shape patient outcomes. Advances in diagnostics and therapeutics offer real potential to reduce the incidence and impact of acute, chronic, and hyperacute rejection, yet realizing that potential requires coordinated action across manufacturers, clinicians, health systems, and policymakers. Strategic investments in noninvasive monitoring, evidence generation, interoperable workflows, and resilient supply chains are central to translating scientific progress into routine clinical benefit.

In conclusion, stakeholders that align product development with clinical workflows, prioritize real-world validation, and invest in regional implementation strategies will be best positioned to improve graft survival and patient quality of life. Continued collaboration between hospitals and transplant centers, research institutes, and specialty clinics will drive the next wave of innovation and ensure that technological advances deliver measurable clinical value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Solid Organ Transplantation Rejection Market, by Rejection Type

  • 8.1. Acute Rejection
  • 8.2. Chronic Rejection
  • 8.3. Hyperacute Rejection

9. Solid Organ Transplantation Rejection Market, by Offering

  • 9.1. Diagnosis & Testing Solutions
    • 9.1.1. Blood Tests
    • 9.1.2. Imaging Tests
    • 9.1.3. Tissue Biopsy
  • 9.2. Medications
    • 9.2.1. Antibodies
    • 9.2.2. Antimetabolites
    • 9.2.3. Calcineurin Inhibitors
    • 9.2.4. Steroids

10. Solid Organ Transplantation Rejection Market, by Organ Type

  • 10.1. Heart
  • 10.2. Kidney
  • 10.3. Liver
  • 10.4. Lung
  • 10.5. Pancreas

11. Solid Organ Transplantation Rejection Market, by End User

  • 11.1. Hospitals & Transplant Centers
  • 11.2. Research Institutes
  • 11.3. Specialty Clinics

12. Solid Organ Transplantation Rejection Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Solid Organ Transplantation Rejection Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Solid Organ Transplantation Rejection Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Solid Organ Transplantation Rejection Market

16. China Solid Organ Transplantation Rejection Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Accord Healthcare Limited
  • 17.7. Asahi Kasei Corporation
  • 17.8. Astellas Pharma Inc.
  • 17.9. Biocon
  • 17.10. Cipla Ltd.
  • 17.11. Dr. Reddy's Laboratories Ltd.
  • 17.12. Eurofins Transplant Diagnostics
  • 17.13. F. Hoffmann-La Roche Ltd.
  • 17.14. GlaxoSmithKline PLC
  • 17.15. Globela Pharma
  • 17.16. Lupin Limited
  • 17.17. Manus Aktteva Biopharma LLP
  • 17.18. Natco Pharma Ltd.
  • 17.19. Novartis AG
  • 17.20. Panacea Biotec Pharma Ltd.
  • 17.21. Pfizer Inc.
  • 17.22. Plexision
  • 17.23. Sanofi S.A.
  • 17.24. Strides Pharma Global Pte Ltd.
  • 17.25. Thermo Fisher Scientific Inc.
  • 17.26. Veloxis Pharmaceuticals A/S
  • 17.27. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ACUTE REJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ACUTE REJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ACUTE REJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CHRONIC REJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CHRONIC REJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CHRONIC REJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HYPERACUTE REJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HYPERACUTE REJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HYPERACUTE REJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY KIDNEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LIVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LIVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY PANCREAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY PANCREAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY PANCREAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 136. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 137. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 138. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. G7 SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. G7 SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 157. G7 SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 158. G7 SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 159. G7 SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. G7 SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. NATO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NATO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 164. NATO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 165. NATO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 166. NATO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. NATO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)